Swiss National Bank Ultragenyx Pharmaceutical Inc. Transaction History

Swiss National Bank

  • $137 Billion
  • Q1 2025

A detailed history of Swiss National Bank transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Swiss National Bank holds 161,052 shares of RARE stock, worth $5.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,052
Previous 163,152 1.29%
Holding current value
$5.7 Million
Previous $6.86 Million 15.04%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$36.21 - $45.78 $76,041 - $96,138
-2,100 Reduced 1.29%
161,052 $5.83 Million
Q4 2024

Feb 10, 2025
BUY
$42.07 - $57.72 $168,280 - $230,880
4,000 Added 2.51%
163,152 $6.86 Million
Q3 2024

Nov 07, 2024
BUY
$40.21 - $59.36 $534,793 - $789,488
13,300 Added 9.12%
159,152 $8.84 Million
Q1 2024

May 07, 2024
BUY
$43.02 - $53.69 $184,986 - $230,867
4,300 Added 3.04%
145,852 $6.81 Million
Q4 2023

Feb 06, 2024
SELL
$31.73 - $49.19 $447,393 - $693,579
-14,100 Reduced 9.06%
141,552 $6.77 Million
Q3 2023

Nov 08, 2023
BUY
$34.92 - $46.66 $97,776 - $130,647
2,800 Added 1.83%
155,652 $5.55 Million
Q2 2023

Aug 09, 2023
BUY
$37.35 - $52.15 $339,885 - $474,565
9,100 Added 6.33%
152,852 $7.05 Million
Q1 2023

May 10, 2023
SELL
$36.99 - $48.71 $625,131 - $823,199
-16,900 Reduced 10.52%
143,752 $5.76 Million
Q4 2022

Feb 08, 2023
BUY
$33.72 - $46.33 $104,532 - $143,623
3,100 Added 1.97%
160,652 $7.44 Million
Q3 2022

Nov 09, 2022
BUY
$39.96 - $66.14 $91,908 - $152,122
2,300 Added 1.48%
157,552 $6.52 Million
Q2 2022

Aug 09, 2022
BUY
$45.8 - $85.4 $96,180 - $179,340
2,100 Added 1.37%
155,252 $9.26 Million
Q1 2022

May 09, 2022
BUY
$62.2 - $84.4 $702,860 - $953,720
11,300 Added 7.97%
153,152 $11.1 Million
Q4 2021

Feb 08, 2022
BUY
$73.71 - $87.86 $14,741 - $17,572
200 Added 0.14%
141,852 $11.9 Million
Q3 2021

Nov 08, 2021
BUY
$77.92 - $102.4 $116,880 - $153,600
1,500 Added 1.07%
141,652 $12.8 Million
Q2 2021

Aug 06, 2021
SELL
$92.19 - $115.71 $313,446 - $393,414
-3,400 Reduced 2.37%
140,152 $13.4 Million
Q1 2021

May 07, 2021
BUY
$106.9 - $167.73 $1.43 Million - $2.25 Million
13,400 Added 10.3%
143,552 $16.3 Million
Q4 2020

Feb 05, 2021
BUY
$84.4 - $177.39 $126,600 - $266,085
1,500 Added 1.17%
130,152 $18 Million
Q3 2020

Nov 09, 2020
BUY
$72.98 - $90.0 $430,582 - $531,000
5,900 Added 4.81%
128,652 $10.6 Million
Q2 2020

Aug 05, 2020
BUY
$46.91 - $78.22 $764,633 - $1.27 Million
16,300 Added 15.31%
122,752 $9.6 Million
Q1 2020

May 08, 2020
BUY
$33.8 - $62.9 $54,079 - $100,640
1,600 Added 1.53%
106,452 $4.73 Million
Q4 2019

Feb 06, 2020
BUY
$36.08 - $45.83 $72,160 - $91,660
2,000 Added 1.94%
104,852 $4.48 Million
Q3 2019

Nov 12, 2019
BUY
$42.5 - $63.11 $136,000 - $201,952
3,200 Added 3.21%
102,852 $4.4 Million
Q2 2019

Aug 02, 2019
BUY
$54.93 - $74.36 $76,902 - $104,104
1,400 Added 1.42%
99,652 $6.33 Million
Q1 2019

May 10, 2019
BUY
$39.87 - $69.36 $558,180 - $971,040
14,000 Added 16.62%
98,252 $6.82 Million
Q4 2018

Feb 13, 2019
BUY
$38.89 - $77.3 $85,558 - $170,060
2,200 Added 2.68%
84,252 $3.66 Million
Q2 2018

Aug 09, 2018
BUY
$48.54 - $85.31 $213,576 - $375,364
4,400 Added 5.67%
82,052 $6.31 Million
Q1 2018

May 04, 2018
BUY
$44.33 - $58.52 $341,341 - $450,604
7,700 Added 11.01%
77,652 $3.96 Million
Q4 2017

Feb 07, 2018
BUY
$43.54 - $57.32 $117,558 - $154,764
2,700 Added 4.01%
69,952 $3.24 Million
Q3 2017

Nov 03, 2017
BUY
$49.79 - $66.32 $3.35 Million - $4.46 Million
67,252
67,252 $3.58 Million

Others Institutions Holding RARE

# of Institutions
336
Shares Held
88.9M
Call Options Held
1.08M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.48B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email